Obermatt
See Similar Stocks →

10x Genomics

NSQ:TXG · US88025U1097
Life Sciences Tools & ServicesMedium

360

38
Profit price2
Owner Earnings Yield45
Dividend Yield1
Price/Sales28
EV / Gross Profit64
Price/Book19
Return on Capital21
Cash Return on Capital45
Return on Equity40
EBIT Margin25
Gross Profitability91
Accruals85
Owner Earnings Margin45
Sales growth10
Profit growth43
Reinvestment65
Price momentum99
Debt load78
Refinancing29
Debt Payback100
Liquidity1
Analyst ratings19
Opinion Changes50
Price Target Upside3
Market mood36
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

10x Genomics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2012
Employees1,106
Website10xgenomics.com
ISINUS88025U1097
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsBiomedical EngineeringGeneticsBiotechnologyHealth CareScience and Engineering

Description

10x Genomics, Inc. operates as a life sciences technology company. The company focuses on building innovative products and solutions to interrogate, understand and master biology. The company’s integrated research solutions include instruments, cons…

Analysis

Middle-of-the-road

10x Genomics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 373.8×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
17
2023202420252026

All-time high

61

Jan 2024

All-time low

17

Jun 2026

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
28
61
11
9
Price/Earnings
100
12
12
4
Price/Book
19
53
12
6
Dividend Yield
1
1
1
1
Value (overall)
32
55
12
9

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare 10x Genomics with its peers
Standard BioTools
NSQ:LAB
60
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Nautilus Biotechnology
NAQ:NAUT
26
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Seer
NSQ:SEER
43
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Cytek Biosciences
NSQ:CTKB
38
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →